IN 120221
Alternative Names: IN-120221; IN-A003Latest Information Update: 10 Apr 2024
At a glance
- Originator CJ Cheiljedang Corp.
- Developer HK inno.N
- Class Antineoplastics; Purine nucleosides
- Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 31 Jul 2023 Early research in Cancer in South Korea (unspecified route) prior to July 2023 (HK inno.N pipeline, March 2024)
- 31 Jul 2023 Preclinical trials in Cancer in South Korea (unspecified route) (HK inno.N pipeline, March 2024)
- 04 Jul 2023 HK inno.N has patent protection for IN 120221 in South Korea